DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine is a paper indexed in ScholarIQ from OpenAlex.

How many citations does DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine have?

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine has 213 citations in the OpenAlex counts ScholarIQ stores.

When was DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine published?

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine has 2018 year in the ScholarIQ index.

What is the open-access status of DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine?

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine has bronze oa status in the ScholarIQ index.

What is the DOI of DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine?

The DOI for DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine is on the source record.

What is the PMID of DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine?

The PMID for DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine is on the source record.

What is the OpenAlex record for DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine?

The OpenAlex for DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine is on the source record.